A “successful” procedure may have a different meaning to the heart team than to the patient, Misty Theriot stressed.
SAN DIEGO, CA—The novel ProtEmbo device (Protembis) for cerebral embolic protection (CEP) during TAVI is safe to use but does ...
At 6 months, the win ratio favored the device over optimal medical therapy, in large part driven by improved quality of life.
The IRIS-MAIN registry results did show some differences in nonfatal outcomes like stroke, MI, and revascularization.
Underdiagnosis and undertreatment likely drive the profound effects observed in certain populations, says Juan Granada.
SAN DIEGO, CA—Patients treated with the Agent drug-coated balloon (DCB; Boston Scientific) have encouraging outcomes at 1 ...
Michael J. Reardon and C. Michael Gibson discuss the 5-year outcomes of TAVR or SAVR in low-risk patients with AS.
REMEDY-PILOT showed the safety and feasibility of using the device, but with no effects on perfusion or angina symptoms.
The postapproval study makes the case that Symplicity Spyral reduces BP across a wide swath of real-world populations.
Angiography-Derived FFR vs. Usual Care for Lesion Selection and Optimization in All-Comers PCI: Final Results of the PIONEER IV Randomized Trial Receive the the latest news, research, and ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
The rates of TLF were considerably lower than the investigators expected, leading to questions about experience and selection ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results